✦ LIBER ✦

P-238 Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unresetable non-small cell lung cancer (NSCLC)

✍ Scribed by DiSalvo, Wendye M.; Beggs, Virginia L.; Meyers, Louise P.; Dragnev, Konstantin H.; Gibson, Jennifer J.; Hoopes, P. Jack; Strawbridge, Rendall R.; Hammond, Susan; Rigas, James R.

Book ID: 118571939
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 363 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92207-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8LBA Biomarker evaluation in the randomi

8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB